Quale sarebbe il prezzo per Fresh Tracks Therapeutics, Inc. (FRTX)

Il prezzo per Fresh Tracks Therapeutics, Inc. (FRTX) è $0.94

Qual è la capitalizzazione di mercato per Fresh Tracks Therapeutics, Inc. (FRTX)

La capitalizzazione di mercato per Fresh Tracks Therapeutics, Inc. (FRTX) è $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Prezzo e Capitalizzazione di Mercato

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Il prezzo per FRTX	Attivo B	Capitalizzazione del mercato a B	Risultati
$1,876,002 $2.73M	NVDA	$5.452T	+199,574,612.63%
$1,545,028 $2.73M	AAPL	$4.490T	+164,364,578.08%
$1,432,295 $2.73M	GOOG	$4.162T	+152,371,752.22%
$1,265,039 $2.73M	MSFT	$3.676T	+134,578,547.49%
$974,858 $2.73M	AMZN	$2.833T	+103,708,151.11%

Il prezzo per FRTX

Attivo B

Capitalizzazione del mercato a B

Risultati

$1,876,002 $2.73M